Skip to main content

Table 4 The correlation of CDK5 with diverse clinical clinicopathological factors in NSCLC

From: An immunohistochemical study of cyclin-dependent kinase 5 (CDK5) expression in non-small cell lung cancer (NSCLC) and small cell lung cancer (SCLC): a possible prognostic biomarker

NSCLC

n

CDK5 negative (n, %)

CDK5 positive (n, %)

Z

P

Gender

   

−0.406

0.685

 Male

254

126(49.6)

128(50.4)

  

 Female

85

40(47.1)

45(52.9)

  

Age(years)

   

−0.080

0.936

 <60

181

89(49.2)

92(50.8)

  

 ≥60

158

77(48.7)

81(51.3)

  

Pathological grading

   

24.58a

<0.001

 I

39

29(74.4)

10(25.6)

  

 II

92

53(57.6)

39(42.4)

  

 III

130

44(33.8)

86(66.2)

  

TNM

   

−2.376

0.018

 I–II

286

148(51.7)

138(48.3)

  

 III–IV

53

18(34.0)

35(66.0)

  

LNM

   

−6.717

<0.001

 Yes

115

27(23.5))

88(76.5)

  

 No

224

139(62.1)

85(37.9)

  

Tumor diameter (cm)

   

−1.145

0.252

 ≤7

295

148(50.2)

147(49.8)

  

 >7

44

18(40.9)

26(59.1)

  

Distal metastasis

   

−1.962

0.05

 Absent

323

162(50.2)

161(49.8)

  

 Present

16

4(25.0)

12(75.0)

  

Histology

   

3.646a

0.456

 Adenocarcinoma

127

64(50.4)

63(49.6)

  

 Squamous cell carcinoma

175

88(50.3)

87(49.7)

  

 Adenosquamous carcinoma

28

10(35.7)

18(64.3)

  

 Undifferentiated carcinoma

8

3(37.5)

5(62.5)

  

 Large cell carcinoma

1

1(100)

0(0)

  

Adenocarcinoma classification

   

6.508a

0.089

 Acinar adenocarcinoma

83

36(43.4)

47(56.6)

  

 Papillary adenocarcinoma

19

12(63.2)

7(36.8)

  

 Broncholoalveolar cell carcinoma

18

10(55.6)

8(44.4)

  

 Mucinous carcinoma

7

6(85.7)

1(14.3)

  
  1. Pathological grading I vs. II Z = −1.805, P = 0.071, I vs. III Z = −4.466, P < 0.001, II vs. III Z = −3.508, P < 0.001. Acinar adenocarcinoma vs. mucinous Z = −2.144, P = 0.032. There were no differences of expression of CDK5 in other subgroups
  2. aKruskal-Wallis H test was performed when the data were divided into more than two groups